Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Extracellular Vesicle-Associated miRNAs and Chemoresistance: A Systematic Review
Indexado
WoS WOS:000699407700001
Scopus SCOPUS_ID:85114726950
DOI 10.3390/CANCERS13184608
Año 2021
Tipo revisión

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Cancer is a leading public health issue globally, and diagnosis is often associated with poor outcomes and reduced patient survival. One of the major contributors to the fatality resultant of cancer is the development of resistance to chemotherapy, known as chemoresistance. Furthermore, there are limitations in our ability to identify patients that will respond to therapy, versus patients that will develop relapse, and display limited or no response to treatment. This often leads to patients being subjected to multiple futile treatment cycles, and results in a reduction in their quality of life. Therefore, there is an urgent clinical need to develop tools to identify patients at risk of chemoresistance, and recent literature has suggested that small extracellular vesicles, known as exosomes, may be a vital source of information. Extracellular vesicles (EV) are membrane bound vesicles, involved in cell-cell communication, through the transfer of their cargo, which includes proteins, lipids, and miRNAs. A defined exploration strategy was performed in this systematic review in order to provide a compilation of key EV miRNAs which may be predictive of chemoresistance. We searched the PubMed, Science Direct, and Scopus databases using the following keywords: Extracellular vesicles OR exosomes OR EVs AND miRNA AND Chemotherapy OR Chemoresistance OR Cancer Recurrence from 2010 to 2020. We found 31 articles that reported key EV-associated miRNAs involved in cancer recurrence related to chemoresistance. Interestingly, multiple studies of the same tumor type identified different microRNAs, and few studies identified the same ones. Specifically, miR-21, miR-222, and miR-155 displayed roles in response to chemotherapy, and were found to be common in colorectal cancer, ovarian cancer, breast cancer, and diffuse large B cell lymphoma patients (DLBCL). miR-21 and miR-222 were found to favour the development of chemoresistance, whereas miR-155 exhibited a contrasting role, depending on the type of primary tumor. Whilst high levels of miR-155 were found to correlate with chemotherapy resistance in DLBCL, it was found to be predictive of an effective response towards chemotherapy in breast cancer. Thus, further research regarding the roles of these miRNAs would be beneficial in terms of designing novel tools to counteract the progression of cancer in a not-to-distant future.

Revista



Revista ISSN
Cancers 2072-6694

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Oncology
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 CAMPOS-GONZALEZ, AMERICA Hombre UQ Centre for Clinical Research - Australia
UNIV QUEENSLAND - Australia
2 Sharma, Shayna Mujer UQ Centre for Clinical Research - Australia
UNIV QUEENSLAND - Australia
3 Obermair, Andreas Hombre UQ Centre for Clinical Research - Australia
UNIV QUEENSLAND - Australia
4 SALOMON-GALLO, CARLOS FRANCISCO Hombre UQ Centre for Clinical Research - Australia
Universidad del Alba - Chile
UNIV QUEENSLAND - Australia
Univ Alba - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
National Health and Medical Research Council
Lions Medical Research Foundation
Ovarian Cancer Research Foundation
Medical Research Future Fund
Ovarian Cancer Research Foundation (OCRF)
Donald & Joan Wilson Foundation Ltd.
Lion Medical Research Foundation
Becas Chile (ANID Postdoctoral fellowship)

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
This research was supported by The Lion Medical Research Foundation (2015001964), The Medical Research Future Fund (MRF1199984), National Health and Medical Research Council (NHMRC 1195451), The Donald & Joan Wilson Foundation Ltd. (2020000323), Ovarian Cancer Research Foundation (OCRF, 2018001167), and Becas Chile (ANID Postdoctoral fellowship to A.C.). Conflicts of Interest: The authors declare no conflict of interest.
This research was supported by The Lion Medical Research Foundation (2015001964), The Medical Research Future Fund (MRF1199984), National Health and Medical Research Council (NHMRC 1195451), The Donald & Joan Wilson Foundation Ltd. (2020000323), Ovarian Cancer Research Foundation (OCRF, 2018001167), and Becas Chile (ANID Postdoctoral fellowship to A.C.).

Muestra la fuente de financiamiento declarada en la publicación.